New York, NY (August 29, 2025) – TB Alliance announced the appointment of Dr. Soraya Madani as Senior Vice President, Program and Alliance Management. Dr. Madani brings more than 25 years of leadership experience in drug development, regulatory affairs, program leadership, and portfolio management to the organization.
In this role, Dr. Madani will provide strategic cross-functional leadership across TB Alliance’s research and development portfolio, overseeing major partnerships and alliances, including those with leading research and development and manufacturing partners. Dr. Madani will also guide the advancement of late-stage research programs, including the ongoing development of sorfequiline (TBAJ-876).
Dr. Madani has a proven track record of leading therapies from early development through approval and introduction, including leading the development of Uplizna in neuromyelitis optica spectrum disorder (NMOSD). Dr Madani’s career spans senior positions at AstraZeneca, Viela Bio, Novartis, and MedImmune, as well as service as a regulatory reviewer at the U.S. Food and Drug Administration. She holds a Ph.D. in Pharmaceutics from the University of Washington and a B.S. in Chemistry from the State University of New York, New Paltz.
“Soraya’s leadership, deep scientific, regulatory, and program management expertise, will be invaluable as we advance our promising development programs,” said Dr. Mel Spigelman, President and CEO of TB Alliance. “Her demonstrated successes in delivering innovative therapies to people, coupled with her skill in building and guiding high-performing global teams, will strengthen TB Alliance’s ability to rapidly and efficiently bring new TB cures to those who need them most, ensuring mutually beneficial collaborations with partners along the way.”
“I am honored to join TB Alliance and contribute to its mission of developing faster, better, and simpler TB cures to enable the end of tuberculosis,” said Dr. Soraya Madani. “The organization’s commitment to scientific excellence, human impact, and global collaboration aligns with my experience as well as my personal values. I look forward to working with the TB Alliance team and our talented partners around the world to bring new and improved TB treatments through the pipeline and to the millions who need them.”
Dr. Madani most recently served as Global Program Leader, Late Stage at AstraZeneca and as Founder and Principal of Madani Drug Development LLC, where she advised pharmaceutical and biotech companies on strategy across the full spectrum of drug development.
About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Cystic Fibrosis Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Global Disease Eradication Fund (South Korea), Global Health Innovative Technology Fund, Korea International Cooperation Agency, MedAccess, United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP), United States National Institutes for Health – National Center for Advancing Translational Sciences (NCATS), United States National Institutes for Health – National Institute of Allergy and Infectious Diseases (NIAID), Raoul Follerau Foundation, South Korea’s Ministry of Foreign Affairs, Unitaid, and the United States Agency for International Development. For more information, please visit: www.tballiance.org.